A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

Inclusion Criteria:

• ≥18 years old

• Histologically or cytologically confirmed advanced or metastatic malignancies asdefined in the protocol.

• Participants must have experienced disease progression after treatment withavailable therapies, including anti-PD-(L)1 or anti-CTLA4 therapy if applicable,that are known to confer clinical benefit, or who are intolerant to, or ineligiblefor standard treatment. Prior anti-PD-(L)1 therapy should not have been discontinuedbecause of intolerance.

• ECOG performance status score of 0 or 1.

• Willingness to undergo pre- and on-treatment tumor biopsy (core or excisional).Biopsies are mandatory for Part 1b cohorts only.

• Presence of measurable disease according to RECIST v1.1

Exclusion Criteria:

• Any known additional malignancy that is progressing or requires active treatment, orhistory of other malignancy within 2 years

• Not recovered to ≤ Grade 1 or baseline from residual toxicities of prior therapy

• Has active autoimmune disease requiring systemic immunosuppression withcorticosteroids Brain or CNS metastases untreated or that have progressed

• History of organ transplant, including allogeneic stem cell transplantation.

• Received more than 4 prior anticancer regimen(s) for advanced or metastatic disease.

• History of clinically significant or uncontrolled cardiac disease

• Active HBV (or at risk of activation), active HCV, or HIV positive

• Is on chronic systemic steroids (> 10 mg/day of prednisone or equivalent).

• Chronic or current active infectious disease requiring systemic antibiotics,antifungal, or antiviral treatment

• Participants that have been initiated on or had modifications in anticoagulationtherapies within the last 3 months prior to first dose of treatment.

• Significant concurrent, uncontrolled medical condition, eg:

• Cardiovascular: Participants with known vasculitis, aneurisms, and othervascular malformations of clinical significance

• Participants with adequate laboratory values within the protocol defined ranges.